FDA panel recommends approval of COPD drug from GSK, Theravance

04/18/2013 | Bloomberg Businessweek

An FDA panel recommended approval of GlaxoSmithKline and Theravance's Breo Ellipta dry powder inhaler to address chronic obstructive pulmonary disease. The agency could decide on the drug's approval by May 12.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY